<?xml version="1.0" encoding="UTF-8"?>
<p id="Par29">The first clinically relevant mAb approved by the FDAÂ was orthoclone OKT3, an anti-CD3 antibody targeting T cells, in 1985, as a prophylaxis for organ transplant patients [
 <xref ref-type="bibr" rid="CR112">112</xref>]. As the field evolved, the steady progression towards harnessing and arming the immune system to combat transformed cells intensified, leading to the discovery of rituximab, an anti-CD20 B-cell receptor antibody and the first successful mAb therapy approved for the treatment of hematological B-cell lymphoma [
 <xref ref-type="bibr" rid="CR113">113</xref>].
</p>
